

1. **Yu WR**, Peng TC, Yeh HL, Kuo HC. Anxiety severity does not influence treatment outcomes in patients with interstitial cystitis/bladder pain syndrome. *Neurourol Urodyn*. 2019 Aug;38(6):1602-1610. doi: 10.1002/nau.24019. Epub 2019 May 6.
2. **Yu WR**, Jhang JF, Ho HC, Jiang YH, Lee CL, Hsu YH, Kuo HC. Cystoscopic hydrodistention characteristics provide clinical and long-term prognostic features of interstitial cystitis after treatment. *Sci Rep*. 2021 Jan 11;11(1):455. doi: 10.1038/s41598-020-80252-x.
3. **Yu WR**, Chang WC, Kuo HC. Voiding dysfunctions in patients with non-Hunner's ulcer interstitial cystitis/bladder pain syndrome do not affect long-term treatment outcome. *Int J Clin Pract*. 2021 Sep;75(9): e14372. doi: 10.1111/ijcp.14372. Epub 2021 May 29.
4. **Yu WR**, Jiang YH, Jhang JF, Kuo HC. Use of Urinary Cytokine and Chemokine Levels for Identifying Bladder Conditions and Predicting Treatment Outcomes in Patients with Interstitial Cystitis/Bladder Pain Syndrome. *Biomedicines*. 2022 May 17;10(5):1149. doi: 10.3390/biomedicines10051149. PMID: 35625885;
5. **Yu WR**, Kuo HC. Usefulness of videourodynamic study in the decision-making of surgical intervention and bladder management for neurogenic lower urinary tract dysfunction among patients with myelomeningocele. *Int Urol Nephrol*. 2022 Aug;54(8):1815-1824. doi: 10.1007/s11255-022-03236-y. Epub 2022 May 24.
6. **Yu WR**, Chang WC, Kuo HC. Clinical presentation, videourodynamic characteristics, and treatment outcome in men with interstitial cystitis-like lower urinary tract symptoms. *Int Urol Nephrol*. 2022 Sep;54(9):2157-2165. doi: 10.1007/s11255-022-03294-2. Epub 2022 Jul 8.
7. **Yu WR**, Jhang JF, Chen BY, Ou SR, Li HM, Kuo HC. Multimodal Treatment with Cognitive Behavioral Therapeutic Intervention Plus Bladder Treatment Is More Effective than Monotherapy for Patients with Interstitial Cystitis/Bladder Pain Syndrome-A Randomized Clinical Trial. *J Clin Med*. 2022 Oct 21;11(20):6221. doi: 10.3390/jcm11206221.
8. **Yu WR**, Chuang FC, Chang WC, Kuo HC. Pelvic Floor Myofascial Pain Might Influence Treatment Outcome of Interstitial Cystitis/Bladder Pain Syndrome: A Prospective Study. *Pain Physician*. 2022 Nov;25(8): E1315-E1322.
9. **Yu WR**, Jiang YH, Jhang JF, Chang WC, Kuo HC. Treatment Outcomes of Intravesical Botulinum Toxin A Injections on Patients with Interstitial Cystitis/Bladder Pain Syndrome. *Toxins (Basel)*. 2022 Dec 11;14(12):871. doi: 10.3390/toxins14120871.
10. **Yu WR**, Jiang YH, Jhang JF, Kuo HC. Use of Urinary Biomarkers in Discriminating Interstitial Cystitis/Bladder Pain Syndrome from Male Lower Urinary Tract Dysfunctions. *Int J Mol Sci*. 2023 Jul 27;24(15):12055. doi: 10.3390/ijms241512055.
11. **Yu WR**, Kuo HC. Multimodal therapies and strategies for the treatment of interstitial cystitis/bladder pain syndrome in Taiwan. *Low Urin Tract Symptoms*. 2024;16(1):e12508. doi:10.1111/luts.12508
12. **Yu WR**, Jiang YH, Jhang JF, Kuo HC. Cystoscopic characteristic findings of interstitial cystitis and clinical implications. *Tzu Chi Med J*. 2023;36(1):30-37. Published 2023 Aug 22. doi: 10.4103/tcmj.tcmj_172_23
13. **Yu WR**, Jhang JF, Kuo HC. Intravesical Botulinum Toxin Injection Plus Hydrodistention Is More Effective in Patients with Bladder Pain-Predominant Interstitial Cystitis/Bladder Pain Syndrome. *Toxins (Basel)*. 2024;16(2):74. Published 2024 Feb 1. doi:10.3390/toxins16020074
14. Jhang JF, **Yu WR**, Huang WT, Kuo HC. Combination of urinary biomarkers and machine-learning models provided a higher predictive accuracy to predict long-term treatment outcomes of patients with interstitial cystitis/bladder pain syndrome. *World J Urol*. 2024;42(1):173. Published 2024 Mar 20. doi:10.1007/s00345-024-04843-3
15. **Yu WR**, Jiang YH, Jhang JF, Kuo HC. Urine biomarker could be a useful tool for differential diagnosis of a lower urinary tract dysfunction. *Tzu Chi Med J*. 2023;36(2):110-119. Published 2023 Dec 13. doi: 10.4103/tcmj.tcmj_221_23
16. **Yu WR**, Tian JH, Kuo HC. Efficacy of Urethral Sphincter Botulinum Toxin A Injection in Patients with Spinal Cord Injury with Dysuria: A Retrospective Cohort Study. *Toxins (Basel)*. 2024;16(8):336. Published 2024 Jul 31. doi:10.3390/toxins16080336

17. **Yu WR**, Jhang JF, Jiang YH, Kuo HC. The Pathomechanism and Current Treatments for Chronic Interstitial Cystitis and Bladder Pain Syndrome. *Biomedicines*. 2024;12(9):2051. Published 2024 Sep 10. doi:10.3390/biomedicines12092051
18. **Yu WR**, Jhang JF, Jiang YH, Kuo HC. Pelvic floor muscle pain is associated with higher symptom scores and bladder pain perception in women with interstitial cystitis and bladder pain syndrome. *World J Urol*. 2024;43(1):9. Published 2024 Dec 3. doi:10.1007/s00345-024-05366-7
19. **Yu WR**, Jiang YH, Jhang JF, Kuo HC. Repeated intravesical injections of platelet-rich plasma are safe and effective in the treatment of interstitial cystitis/bladder pain syndrome. *Tzu Chi Med J*. 2024;37(1):72-79. Published 2024 Oct 16. doi: 10.4103/tcmj.tcmj_166_24
20. **Yu WR**, Jiang YH, Jhang JF, Kuo HC. Focal or diffuse bladder wall thickness on bladder computed tomography indicates more severe bladder wall inflammation in patients with interstitial cystitis. *World J Urol*. 2025;43(1):100. Published 2025 Feb 4. doi:10.1007/s00345-025-05451-5
21. Tian JH, Tsai CY, **Yu WR**, Jiang YH, Jhang JF, Kuo HC. Clustering of Urinary Biomarkers to Identify Interstitial Cystitis Subtypes and Different Clinical Characteristics and Treatment Outcomes. *Biomedicines*. 2025;13(2):369. Published 2025 Feb 5. doi:10.3390/biomedicines13020369
22. Jhang JF, **Yu WR**, Jiang YH, Kuo HC. Pathophysiology and potential multimodal therapeutic strategies for IC/BPS. *Nat Rev Urol*. Published online May 15, 2025. doi:10.1038/s41585-025-01044-4



Book

- 李彥範、辛孟娟、邱子瑄、林怡岑、曾寶慧、游婉茹 (2021)·護理新人不要怕，焦點交班不費力。金名；台北。
- 李彥範、辛孟娟、邱子瑄、林怡岑、曾寶慧、游婉茹 (2023)·護理新人不要怕，焦點交班不費力—第二版。金名；台北。